Documentos clave

Ver Toda la documentación

Saltar a

L1920

LY255283

Name: LY255283
Brand: SIGMA

≥98% (HPLC), powder

Sinónimos:

1-(5-Ethyl-2-hydroxy-4-(6-methyl-6-(1H-tetrazol-5-yl)heptyloxy)phenyl)ethanone

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Cambiar Vistas

Tamaño de envase	SKU	Disponibilidad	Precio

Acerca de este artículo

Fórmula empírica (notación de Hill):

C₁₉H₂₈N₄O₃

Número CAS:

117690-79-6

Peso molecular:

360.45

NACRES:

NA.77

PubChem Substance ID:

329817396

UNSPSC Code:

12352204

MDL number:

MFCD00876422

Assay:

≥98% (HPLC)

Form:

powder

Quality level:

100

Para consultas sobre este producto L1920, póngase en contacto con su oficina o distribuidor locales de Merck. Póngase en contacto con el Servicio técnico

Servicio técnico

¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.

Permítanos ayudarle

Propiedades

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

off-white to light yellow

solubility

DMSO: >20 mg/mL

originator

Eli Lilly

storage temp.

−20°C

SMILES string

CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c2nnn[nH]2

InChI

1S/C19H28N4O3/c1-5-14-11-15(13(2)24)16(25)12-17(14)26-10-8-6-7-9-19(3,4)18-20-22-23-21-18/h11-12,25H,5-10H2,1-4H3,(H,20,21,22,23)

InChI key

WCGXJPFHTHQNJL-UHFFFAOYSA-N

Descripción

Application

LY255283, a competitive leukotriene B4 receptor antagonist, is used in leukotriene receptor research along with other selective leukotriene receptor agonists and antagonist to identify and differentiate the physiological and cell signaling effects of the leukotriene B4 receptor on processes such as paclitaxel resistance in MCF-7/DOX breast cancer cells, monocyte-derived dendritic cell chemotaxis, and 5-lipoxygenase activity and interleukin-8 production in human neutrophils.[1] LY255283 may be used to help verify that an observed process or cell event is leukotriene B4 receptor-dependent.[1]

Biochem/physiol Actions

LY255283 is a competitive leukotriene B₄ receptor antagonist, specific to the BLT2 receptor subtype.

LY255283 is a competitive leukotriene B₄ receptor antagonist, with an IC₅₀ of about 100 nM. It is somewhat selective for the BLT2 receptor, since IC₅₀ values at the BLT1 receptor are >10 μM. LY255283 reduces airway obstruction in animal models of asthma.

Features and Benefits

This compound was developed by Eli Lilly. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Comparar elementos similares

Ver comparación completa

Mostrar Diferencias

1 of 1

Este artículo	S8822	SML1391	SML1276
Sigma-Aldrich L1920 LY255283	Sigma-Aldrich S8822 SB-525334	Sigma-Aldrich SML1391 Olmesartan medoxomil	Sigma-Aldrich SML1276 BAZ2-ICR
form powder	form solid	form powder	form powder
assay ≥98% (HPLC)	assay ≥98% (HPLC)	assay ≥98% (HPLC)	assay ≥98% (HPLC)
Quality Level 100	Quality Level 100	Quality Level 100	Quality Level 100
storage temp. −20°C	storage temp. 2-8°C	storage temp. 2-8°C	storage temp. 2-8°C
solubility DMSO: >20 mg/mL	solubility DMSO: ≥20 mg/mL	solubility DMSO: 10 mg/mL, clear	solubility DMSO: 10 mg/mL, clear
originator Eli Lilly	originator GlaxoSmithKline	originator -	originator -

Clase de almacenamiento

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

069K4605V

069K4605

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Artículos

Discover Bioactive Small Molecules for Lipid Signaling Research

A novel leukotriene B4-receptor antagonist in endotoxin shock: a prospective, controlled trial in a porcine model.

M P Fink et al.

Critical care medicine, 21(12), 1825-1837 (1993-12-01)

To evaluate the hypothesis that treatment with LY255283, a novel leukotriene B4-receptor antagonist, is beneficial in an animal model of the adult respiratory distress syndrome induced by endotoxin. Prospective, randomized, controlled trial. Laboratory at a large university medical center. Twenty-five

BLT2 promotes the invasion and metastasis of aggressive bladder cancer cells through a reactive oxygen species-linked pathway.

Eun-Young Kim et al.

Free radical biology & medicine, 49(6), 1072-1081 (2010-07-06)

Aggressive bladder cancer is a major cause of morbidity and mortality. Despite the fact that metastatic disease results in death in the majority of bladder cancer cases, the molecular events regulating the invasive phenotype of aggressive bladder cancer are not

Synthetic and structure/activity studies on acid-substituted 2-arylphenols: discovery of 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5- hydroxyphenoxy]-propoxy]phenoxy]benzoic acid, a high-affinity leukotriene B4 receptor antagonist.

J S Sawyer et al.

Journal of medicinal chemistry, 38(22), 4411-4432 (1995-10-27)

Structural derivatives of LY255283 have been studied as receptor antagonists of leukotriene B4. Substitution of the 2-hydroxyacetophenone subunit of 1 (LY255283) with a 2-arylphenol group provided entry into several new series that feature various mono- and diacidic core functionality. These

Ver todos los artículos relacionados

Número de artículo de comercio global

SKU	GTIN
L1920-5MG	04061833024263
L1920-25MG	04061833024256

Preguntas

Revisiones

Sin puntuación